Clinical and diagnosis value of serum Cortisol, TNF-α, albumin in ovarian cancer patients:

Rong Jiang; Xin Pan; Xiu Shi; Jinhua Zhou; Juan Wang; Hong Zhang; Jingjing Ma

doi:10.5937/jomb0-57224

Rong Jiang The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
Xin Pan Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
Xiu Shi Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
Jinhua Zhou Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
Juan Wang Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
Hong Zhang Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China
Jingjing Ma Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, China

DOI: https://doi.org/10.5937/jomb0-57224

Keywords: serum Cortisol, TNF-α, albumin, Advanced ovarian cancer; serum albumin; R0; complications; overall survival

Abstract

Objective: This research aimed to evaluate the prognostic value of serum serum Cortisol, TNF-α, albumin in selecting treatment methods for advanced ovarian cancer (OC) patients.

Methods: A retrospective analysis was conducted on OC patients undergoing surgery at our hospital from June 2022 to June 2024 with complete clinical and pathological data. Patients were categorized into low ALB (< 35 g/L) and normal ALB (≥ 35 g/L) groups based on pretreatment serum ALB levels. Each group was further divided into primary debulking surgery (PDS) and neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) subgroups. Clinicopathologic characteristics were analyzed.

Results: Pretreatment serum ALB levels positively correlated with progression-free survival (PFS) (r = 0.2989, P < 0.05) and overall survival (OS) (r = 0.2702, P < 0.05), with the low ALB group exhibiting significantly lower PFS and OS (P < 0.05). In the low ALB group, significant differences were observed between PDS and NACT-IDS in ascitic fluid level, R0 cytoreduction rate, postoperative complications, and length of stay (P < 0.05), though PFS and OS were comparable (P > 0.05). Similarly, in the normal ALB group, significant differences were noted in FIGO staging, ascitic fluid level, hemoglobin (HGB) levels, intraoperative hemorrhage, blood transfusion volume, R0 cytoreduction rate, and length of stay (P < 0.05), while PFS and OS remained unaffected by treatment type (P > 0.05). Additionally, C-reactive protein (CRP) levels were significantly higher in the low ALB group (6.5 ± 1.1 mg/L vs. 5.2 ± 1.0 mg/L, P < 0.05), indicating greater inflammation, whereas HGB levels were significantly lower (110.4 ± 15.8 g/L vs. 118.7 ± 10.5 g/L, P = 0.021), reflecting poorer nutritional status. Tumor necrosis factor-alpha (TNF-α) levels showed a non-significant upward trend (P = 0.058), while cortisol levels were similar between groups (P = 0.073).

Conclusion: Selecting NACT-IDS for advanced OC patients with hypoalbuminemia can reduce incidence of postoperative complications and elevate cytoreductive effect. Thus, hypoalbuminemia can serve as a reference indicator for advanced OC patients to choose NACT-IDS.

References

1. Sumanth, N., et al., A study to assess the co-morbidities and complications of polycystic ovarian syndrome. Cell. Mol. Biomed. Rep., 2023. 3(2): p. 107-113.
2. Saravani, K., S. Saravani, and F. Dadras, Investigating attitudinal barriers to breast cancer mammography screening among women in Zabol city. Cell. Mol. Biomed. Rep., 2021. 1(4): p. 158-167.
3. Renato, S., et al., Ovarian tissue biopsy for cryopreservation by vaginal natural orifice transluminal endoscopic surgery (vNOTES): a new approach for a minimal invasive ovarian biopsy. Fertil Steril, 2024.
4. Tourang, M., et al., Association between Human Endogenous Retrovirus K gene expression and breast cancer. Cell. Mol. Biomed. Rep., 2021. 1(1): p. 7-13.
5. Pernilla, D.-K., et al., Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study. Gynecol Oncol, 2024. 186.
6. Atsushi, F., et al., Ovarian surveillance including endometrial cytology for patients with hereditary breast and ovarian cancer before risk-reducing salpingo-oophorectomy: A retrospective analysis. J Obstet Gynaecol Res, 2024.
7. Shashank, S., et al., Upfront debulking surgery or delayed surgery after neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer: Comparison of survival from a noncancer center in India. Indian J Cancer, 2023.
8. Hong, L., et al., A retrospective analysis for investigating the relationship between FIGO stage IVA/IVB and cytoreductive surgery with prognosis in epithelial ovarian cancer. Front Oncol, 2023. 13.
9. Claudia, M., et al., Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: Results from the randomised SCORPION trial (NCT01461850). BJOG, 2023. 130.
10. Kenji, Y., et al., Does the geriatric nutrition risk index predict the prognosis of patients with oral squamous cell carcinoma? Br J Oral Maxillofac Surg, 2022. 60.
11. Cyrus, M., et al., Serum Albumin Kinetics in Major Ovarian, Gastrointestinal, and Cervico Facial Cancer Surgery. Int J Environ Res Public Health, 2022. 19.
12. Zhang, M., et al., Trends in nutritional status and factors affecting prognostic nutritional index in ovarian cancer patients during chemotherapy: a prospective longitudinal study based on generalized estimating equations. Support Care Cancer, 2024. 32.
13. Naoko, K., et al., Significance of Pretreatment C-Reactive Protein, Albumin, and C-Reactive Protein to Albumin Ratio in Predicting Poor Prognosis in Epithelial Ovarian Cancer Patients. Nutr Cancer, 2020. 73.
14. Yuanyuan, L., et al., Combined impact of hypoalbuminemia and pharmacogenomic variants on voriconazole trough concentration: data from a real-life clinical setting in the Chinese population. J Chemother, 2023.
15. Yixuan, Z., et al., Magnetically actuated sonodynamic nanorobot collectives for potentiated ovarian cancer therapy. Front Bioeng Biotechnol, 2024. 12.
16. Malika, K., et al., Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis. J Gynecol Oncol, 2022. 33.
17. Shi-Xue, X., et al., Role of albumin-bilirubin score in non-malignant liver disease. World J Gastroenterol, 2024. 30.
18. Da-Wei, Z., et al., Association between postoperative hypoalbuminemia and postoperative pulmonary imaging abnormalities patients undergoing craniotomy for brain tumors: a retrospective cohort study. Sci Rep, 2022. 12.
19. Diwen, L. and Z. Yijun, Predictive Value of Systemic Immune Inflammation Index in Septic Patients with Acute Kidney Injury. Arch Esp Urol, 2024. 77.
20. Sylwia, K., et al., Analysis of the influence of selected protein markers as markers of nutritional status and inflammation on the occurrence of eventration after laparotomy. Pol Przegl Chir, 2024. 96.
21. Chuan-Long, Z., et al., Independent predictive value of blood inflammatory composite markers in ovarian cancer: recent clinical evidence and perspective focusing on NLR and PLR. J Ovarian Res, 2023. 16.
22. Shinji, O., et al., Clinical Utility of the Geriatric Nutritional Risk Index Before Surgical Intervention for Epithelial Ovarian Cancer Patients: A Retrospective Study. J Clin Med Res, 2022. 14.
23. Ruoyao, Z., et al., Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer. World J Surg Oncol, 2023. 21.